The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Systemic miRNA-195 Differentiates Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and Early Stage Disease
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Describe the site-specific dysregulation of some miRNAs and explain their potential as non-invasive biomarkers for diagnosis, prognostication, or markers of treatment response.Cite the characteristics reflected by circulating miR-195 and explain how elevated levels could be used as a breast tumor marker. CME This article is available for continuing medical education credit at CME.TheOncologist.com Purpose.: The potential of microRNAs (miRNAs) as novel tumor markers has been the focus of recent scrutiny because of their tissue specificity, stability, and association with clinicopathological parameters. Data have emerged documenting altered systemic miRNA expression across a spectrum of cancers; however, it remains uncertain as to whether circulating miRNAs are tumor specific. Our aim was to assess a panel of cancer-associated miRNAs in the circulation of patients with various malignancies, to determine whether these “oncomirs” were tumor specific, and thus to establish whether systemic miRNA analysis has utility in cancer diagnosis. Patients and Methods.: Whole blood samples were prospectively collected from preoperative cancer patients (breast, prostate, colon, and renal cancer and melanoma; n = 163) and healthy age- and sex-matched controls (n = 63). Total RNA was isolated, and a panel of seven miRNAs was quantified by real-time quantitative polymerase chain reaction in each sample. Results.: Differential expression of the general oncomirs let 7a, miR-10b, and miR-155, was observed in the majority of cancer patients in a nonspecific manner. Significantly, elevated circulating miR-195 was found to be breast cancer specific and could differentiate breast cancer from other cancers and from controls with a sensitivity of 88% at a specificity of 91%. A combination of three circulating miRNAs, including miR-195, further enhanced the discriminative power of this test for breast cancer to 94%. Conclusion.: These findings suggest that individual cancers display specific systemic miRNA profiles, which could aid in discriminating among cancer types. This finding is of notable clinical consequence because it illustrates the potential of systemic miRNAs as sensitive, specific, noninvasive cancer biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
microRNAs as oncogenes and tumor suppressors
Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.028 · Cited by 2,749
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Reduced accumulation of specific microRNAs in colorectal neoplasia.
Michael, M., Connor, S. M. O., Pellekaan, N. V. H., Young, G. P., & James, R. J. (2003) · PubMed · Cited by 1,775
Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F., Boultwood, J., Wainscoat, J. S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07077.x · Cited by 1,735
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., Shingara, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1083 · Cited by 1,224
Ng, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151
Modulation of microRNA processing by p53
Suzuki, H. I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., & Miyazono, K. (2009) · Nature · doi:10.1038/nature08199 · Cited by 1,124
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
miR-155 gene: A typical multifunctional microRNA
Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.013 · Cited by 815
Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., Fedele, V., Ginzinger, D. G., Getts, R. C., & Haqq, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-24 · Cited by 787
Kong, W., Yang, H., He, L., Zhao, J.-J., Coppola, D., Dalton, W. S., & Cheng, J. Q. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00941-08 · Cited by 689
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181cc939f · Cited by 687
Self-citationResnick, K. E., Alder, H., Hagan, J. P., Richardson, D. L., Croce, C. M., & Cohn, D. E. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.036 · Cited by 647
Chin, L. J., Ratner, E., Leng, S., Zhai, R., Nallur, S., Babar, I., Muller, R.-U., Straka, E., Su, L., Burki, E. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2129 · Cited by 632
How Do MicroRNAs Regulate Gene Expression?
Jackson, R. J., & Standart, N. (2007) · Science's STKE · doi:10.1126/stke.3672007re1 · Cited by 475
Davoren, P. A., McNeill, R. E., Lowery, A. J., Kerin, M. J., & Miller, N. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-76 · Cited by 257
Self-citationAn autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., Di Lauro, R., & Verde, P. (2009) · Oncogene · doi:10.1038/onc.2008.370 · Cited by 242
Moore, R. G., Brown, A. K., Miller, M. C., Badgwell, D., Lu, Z., Allard, W. J., Granai, C. O., Bast, R. C., & Lu, K. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.002 · Cited by 229
Skates, S. J., Horick, N., Yu, Y., Xu, F.-J., Berchuck, A., Havrilesky, L. J., de Bruijn, H. W. A., van der Zee, A. G. J., Woolas, R. P., Jacobs, I. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.091 · Cited by 170
MicroRNAs as Novel Biomarkers for Breast Cancer
Heneghan, H., Miller, N., Lowery, A., Sweeney, K. J., & Kerin, M. J. (2009) · Journal of Oncology · doi:10.1155/2010/950201 · Cited by 164
Self-citationLowery, A., Miller, N., McNeill, R. E., & Kerin, M. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0992 · Cited by 156
Self-citationMicroRNAs in malignant progression
Ma, L., & Weinberg, R. A. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5547 · Cited by 136
Prognostic Value of Serum CA 19–9 Levels in Pancreatic Adenocarcinoma
Tian, F., Appert, H. E., Myles, J. L., & Howard, J. M. (1992) · Annals of Surgery · doi:10.1097/00000658-199204000-00008 · Cited by 115
Herszényi, L., Farinati, F., Cardin, R., István, G., Molnár, L. D., Hritz, I., Paoli, M. D., Plebani, M., & Tulassay, Z. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-194 · Cited by 114
Zhang, H., Su, S.-B., Zhou, Q., & Lu, Y.-Y. (2009) · PubMed · Cited by 18
Cited by
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
MicroRNA as Biomarkers and Diagnostics
Wang, J., Chen, J., & Sen, S. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25056 · Cited by 793
“In view of these findings, differentially abundantmiRNAs detected in blood (Heneghan et al., 2010), cystic fluid (Wang et al., 2015), plasma (Wang et al., 2009; Huang et al., 2010), pancreatic juice (Wang et al., 2014a), serum (Chen et al., 2008b), sputum (Xing et al., 2010), and urine (Ben-Dov et…”
BackgroundThe role of microRNAs in human diseases
Tüfekci, K. U., Öner, M. G., Meuwissen, R. L. J., & Genç, Ş. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-748-8_3 · Cited by 566
Long non-coding RNAs in Huntington's disease neurodegeneration
Johnson, R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.006 · Cited by 398
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J., Malone, C., McLaughlin, R., & Kerin, M. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 374
Self-citation
Metadata
- Authors
- Heneghan, H. M., Miller, N., Kelly, R., Newell, J., & Kerin, M. J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-24
- Volume
- 15
- Issue
- 7
- Pages
- 673-682
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2165347828
- Cited by
- 315
- References
- 36
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.